-
公开(公告)号：US20090291945A1
公开(公告)日：2009-11-26
申请号：US12419722
申请日：2009-04-07
申请人： Gen Unoki , Takashi Hayamizu , Hiroshi Eguchi , Yumiko Muroga , Toshiyuki Kaneko , Naoki Yajima
发明人： Gen Unoki , Takashi Hayamizu , Hiroshi Eguchi , Yumiko Muroga , Toshiyuki Kaneko , Naoki Yajima
IPC分类号： A61K31/54 , A61K31/535 , A61K31/445 , A61K31/165 , C07D279/12 , C07D265/28 , C07D211/60 , C07C237/02
CPC分类号： C07C255/16 , C07C237/10 , C07C237/14 , C07C237/20 , C07C237/24 , C07C259/06 , C07C317/18 , C07C317/28 , C07C317/32 , C07C323/12 , C07C323/41 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07D209/34 , C07D211/60 , C07D211/62 , C07D213/26 , C07D213/40 , C07D231/12 , C07D231/14 , C07D233/61 , C07D265/30 , C07D295/155 , C07D295/185 , C07D317/50 , C07D401/12
摘要： To provide a compound having an excellent cysteine protease inhibitory effect, and to provide a drug for treatment or prevention of the disease selected from the group consisting of osteoporosis, osteoarthritis, chronic rheumatoid arthritis, Paget's disease of bone, hypercalcemia, bone metastasis of cancer, and ostealgia. A compound represented by formula (1) or a pharmaceutically acceptable salt thereof, or a drug or pharmaceutical composition containing the same as an effective component.
摘要翻译： 提供具有优异的半胱氨酸蛋白酶抑制作用的化合物，提供治疗或预防选自骨质疏松症，骨关节炎，慢性类风湿性关节炎，骨关节炎，高钙血症，癌症骨转移的疾病的药物， 和骨痛。 由式（1）表示的化合物或其药学上可接受的盐，或其含有与有效成分相同的药物或药物组合物。
-
公开(公告)号：US06362177B1
公开(公告)日：2002-03-26
申请号：US09905078
申请日：2001-07-16
申请人： Tatsuki Shiota , Ken-ichiro Kataoka , Minoru Imai , Takaharu Tsutsumi , Masaki Sudoh , Ryo Sogawa , Takuya Morita , Takahiko Hada , Yumiko Muroga , Osami Takenouchi , Minoru Furuya , Noriaki Endo , Christine M. Tarby , Wilna Moree , Steven Teig
发明人： Tatsuki Shiota , Ken-ichiro Kataoka , Minoru Imai , Takaharu Tsutsumi , Masaki Sudoh , Ryo Sogawa , Takuya Morita , Takahiko Hada , Yumiko Muroga , Osami Takenouchi , Minoru Furuya , Noriaki Endo , Christine M. Tarby , Wilna Moree , Steven Teig
IPC分类号： A61K3155
CPC分类号： C07D207/325 , A61K31/166 , A61K31/341 , A61K31/343 , A61K31/381 , A61K31/401 , A61K31/404 , A61K31/42 , C07D207/34 , C07D207/416 , C07D209/08 , C07D209/42 , C07D213/65 , C07D213/75 , C07D213/81 , C07D213/82 , C07D231/14 , C07D231/16 , C07D235/16 , C07D239/52 , C07D249/18 , C07D261/08 , C07D263/56 , C07D263/58 , C07D271/06 , C07D285/14 , C07D307/14 , C07D307/68 , C07D317/50 , C07D317/60 , C07D319/18 , C07D333/16 , C07D333/20 , C07D333/38 , C07D333/42 , C07D333/68 , C07D405/06 , C07D407/12 , C07D409/06 , C07D413/12 , C07D487/04 , C07D495/04 , C07D513/04
摘要： A compound represented by the general formula (I), a pharmaceutically acceptable acid addition salt thereof or a pharmaceutically acceptable C1-C6 alkyl addition salt thereof, and their medical applications. These compounds inhibit the action of chemokines such as MIP-1&agr; and/or MCP-1 on target cells, and are useful as therapeutic and/or preventative drugs in diseases, such as atheroclerosis, rheumatoid arthritis, and the like where blood monocytes and lymphocytes infiltrate into tissues.
摘要翻译： 由通式（I）表示的化合物，其药学上可接受的酸加成盐或其药学上可接受的C1-C6烷基加成盐及其医疗应用。 这些化合物抑制趋化因子如MIP-1α和/或MCP-1对靶细胞的作用，并且可用作疾病中的治疗和/或预防药物，例如动脉硬化症，类风湿性关节炎等，其中血液单核细胞和淋巴细胞 渗入组织。
-
公开(公告)号：US06410566B1
公开(公告)日：2002-06-25
申请号：US09905077
申请日：2001-07-16
申请人： Tatsuki Shiota , Ken-ichiro Kataoka , Minoru Imai , Takaharu Tsutsumi , Masaki Sudoh , Ryo Sogawa , Takuya Morita , Takahiko Hada , Yumiko Muroga , Osami Takenouchi , Minoru Furuya , Noriaki Endo , Christine M. Tarby , Wilna Moree , Steven Teig
发明人： Tatsuki Shiota , Ken-ichiro Kataoka , Minoru Imai , Takaharu Tsutsumi , Masaki Sudoh , Ryo Sogawa , Takuya Morita , Takahiko Hada , Yumiko Muroga , Osami Takenouchi , Minoru Furuya , Noriaki Endo , Christine M. Tarby , Wilna Moree , Steven Teig
IPC分类号： A01N4340
CPC分类号： C07D207/325 , A61K31/166 , A61K31/341 , A61K31/343 , A61K31/381 , A61K31/401 , A61K31/404 , A61K31/42 , C07D207/34 , C07D207/416 , C07D209/08 , C07D209/42 , C07D213/65 , C07D213/75 , C07D213/81 , C07D213/82 , C07D231/14 , C07D231/16 , C07D235/16 , C07D239/52 , C07D249/18 , C07D261/08 , C07D263/56 , C07D263/58 , C07D271/06 , C07D285/14 , C07D307/14 , C07D307/68 , C07D317/50 , C07D317/60 , C07D319/18 , C07D333/16 , C07D333/20 , C07D333/38 , C07D333/42 , C07D333/68 , C07D405/06 , C07D407/12 , C07D409/06 , C07D413/12 , C07D487/04 , C07D495/04 , C07D513/04
摘要： A compound represented by the general formula (I), a pharmaceutically acceptable acid addition salt thereof or a pharmaceutically acceptable C1-C6 alkyl addition salt thereof, and their medical applications. These compounds inhibit the action of chemokines such as MIP-1&agr; and/or MCP-1 on target cells, and are useful as therapeutic and/or preventative drugs in diseases, such as atherosclerosis, rheumatoid arthritis, and the like where blood monocytes and lymphocytes infiltrate into tissues.
摘要翻译： 由通式（I）表示的化合物，其药学上可接受的酸加成盐或其药学上可接受的C 1 -C 6烷基加成盐及其医疗应用。 这些化合物抑制趋化因子如MIP-1α和/或MCP-1对靶细胞的作用，并且可用作疾病中的治疗和/或预防药物，例如动脉粥样硬化，类风湿性关节炎等，其中血液单核细胞和淋巴细胞 渗入组织。
-
公开(公告)号：US07576117B1
公开(公告)日：2009-08-18
申请号：US10031698
申请日：2000-08-04
申请人： Tatsuki Shiota , Masaki Sudoh , Tomonori Yokoyama , Yumiko Muroga , Takashi Kamimura , Akinobu Nakanishi
发明人： Tatsuki Shiota , Masaki Sudoh , Tomonori Yokoyama , Yumiko Muroga , Takashi Kamimura , Akinobu Nakanishi
CPC分类号： C07D207/14 , A61K31/40 , A61K31/445
摘要： A medicine containing, as an active ingredient, a cyclic amine derivative represented by the following formula (I), a pharmaceutically acceptable acid addition salt thereof or a pharmaceutically acceptable C1 to C6 alkyl addition salt thereof. The medicine has an action for treating or preventing diseases in which CCR3 participates, such as asthma and allergic rhinitis.
摘要翻译： 含有下式（I）表示的环状胺衍生物，其药学上可接受的酸加成盐或其药学上可接受的C1〜C6烷基加成盐作为有效成分的药物。 该药物具有治疗或预防CCR3参与疾病的作用，如哮喘和过敏性鼻炎。
-
公开(公告)号：US06451842B1
公开(公告)日：2002-09-17
申请号：US09554562
申请日：2000-05-16
申请人： Tatsuki Shiota , Ken-ichiro Kataoka , Minoru Imai , Takaharu Tsutsumi , Masaki Sudoh , Ryo Sogawa , Takuya Morita , Takahiko Hada , Yumiko Muroga , Osami Takenouchi , Minoru Furuya , Noriaki Endo , Christine M. Tarby , Wilna Moree , Steven Teig
发明人： Tatsuki Shiota , Ken-ichiro Kataoka , Minoru Imai , Takaharu Tsutsumi , Masaki Sudoh , Ryo Sogawa , Takuya Morita , Takahiko Hada , Yumiko Muroga , Osami Takenouchi , Minoru Furuya , Noriaki Endo , Christine M. Tarby , Wilna Moree , Steven Teig
IPC分类号： A61K314025
CPC分类号： C07D207/325 , C07D207/09 , C07D207/14 , C07D207/34 , C07D207/416 , C07D209/08 , C07D209/42 , C07D211/26 , C07D211/56 , C07D211/58 , C07D213/65 , C07D213/75 , C07D213/81 , C07D213/82 , C07D231/14 , C07D231/16 , C07D235/16 , C07D239/52 , C07D249/18 , C07D261/08 , C07D263/56 , C07D263/58 , C07D271/06 , C07D285/14 , C07D307/14 , C07D307/68 , C07D317/50 , C07D317/60 , C07D319/18 , C07D333/16 , C07D333/20 , C07D333/38 , C07D333/42 , C07D333/68 , C07D401/06 , C07D401/12 , C07D405/06 , C07D405/12 , C07D407/12 , C07D409/06 , C07D409/12 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/12 , C07D487/04 , C07D495/04 , C07D513/04
摘要： A compound represented by the general formula (I), a pharmaceutically acceptable acid addition salt thereof or a pharmaceutically acceptable C1-C6 alkyl addition salt thereof, and their medical applications. These compounds inhibit the action of chemokines such as MIP-1&agr; and/or MCP-1 on target cells, and are useful as therapeutic and/or preventative drugs in diseases, such as atherosclerosis, rheumatoid arthritis, and the like where blood monocytes and lymphocytes infiltrate into tissues.
-
-
-
-
搜索结果
5 条记录 (耗时 0.062 秒)
